Table 3. The phenotypic susceptibility to INH and Pto based on the specific mutation patterns of katG and inhA.
| Mutation | Total | Phenotypic INH resistance | Phenotypic Pto resistance | ||
|---|---|---|---|---|---|
| High-level | Low-level | Total | |||
| No. of subjects | 206 (100) | 149 (72.3) | 39 (18.9) | 188 (91.3) | 34 (16.5) |
| katG gene alone | 134 (65.0) | 127 (94.8) | 3 (2.2) | 130 (97.0) | 11 (8.2) |
| MUT1 (+) | 119 (57.8) | 112 (94.1) | 3 (2.5) | 115 (96.6) | 9 (7.6) |
| MUT2 (+) | 8 (3.9) | 8 (100) | 0 (0) | 8 (100) | 2 (25) |
| WT (–)/MUT1 (–)/MUT2 (–) | 7 (3.4) | 7 (100) | 0 (0) | 7 (100) | 0 (0) |
| inhA gene alone | 66 (32.0) | 18 (27.3) | 34 (51.5) | 52 (78.8) | 21 (31.8) |
| MUT1 (+) | 60 (29.1) | 17 (28.3) | 34 (56.7) | 51 (85) | 21 (35) |
| MUT2 (+) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| MUT3A (+) | 1 (0.5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| MUT3B (+) | 1 (0.5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| WT1 (–) and all MUT (–) | 4 (1.9) | 1 (25) | 0 (0) | 1 (25) | 0 (0) |
| WT2 (–) and all MUT (–) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Both gene mutation | 6 (2.9) | 4 (66.7) | 2 (33.3) | 6 (100) | 2 (33.3) |
| katG (MUT1), inhA (MUT1) | 2 (1.0) | 2 (100) | 0 (0) | 2 (100) | 0 (0) |
| katG (MUT1), inhA (WT1 loss) | 1 (0.5) | 0 (0) | 1 (100) | 1 (100) | 0 (0) |
| katG (MUT1), inhA (WT2 loss) | 1 (0.5) | 0 (0) | 1 (100) | 1 (100) | 0 (0) |
| katG (WT loss), inhA (MUT1) | 1 (0.5) | 1 (100) | 0 (0) | 1 (100) | 1 (100) |
| katG (WT loss), inhA (WT2 loss) | 1 (0.5) | 1 (100) | 0 (0) | 1 (100) | 1 (100) |
Values are presented as number (%).
INH: isoniazid; Pto: prothionamide; katG WT: S315 region; katG MUT1, S315T[AGC315ACC]; katG MUT2, S315T[AGC315ACA]); inhA WT1: positions −15 to −16; inhA WT2: positions −8; inhA MUT1: C15T; inhA MUT2, A16G; inhA MUT3A: T8C; inhA MUT3B: T8A.